Retrieve available abstracts of 8 articles: HTML format
Single Articles
June 2025
GAO Y, Ji W, Chen Q The diagnostic significance of the C-reactive protein (CRP) in HIV/TB
coinfection: A systematic review and meta-analysis.
Antivir Ther. 2025;30:13596535251345870. PubMedAbstract available
VAN HEMELRYCK S, Van Landuyt E, Deleu S, Leopold L, et al Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion:
Bioequivalence versus separate agents in healthy participants and acceptability
in children living with human immunodeficiency virus-1.
Antivir Ther. 2025;30:13596535251349336. PubMedAbstract available
April 2025
ELEJE GU, Usman HA, Onubogu CU, Fiebai PO, et al Seroprevalence, seroconversion, and mother-to-child transmission of dual and
triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A
national multicentre prospective cohort study.
Antivir Ther. 2025;30:13596535251333259. PubMedAbstract available
PALLANZA M, Thoueille P, Briki M, Alves Saldanha S, et al Sustained viral suppression with once daily dolutegravir-containing regimen in
presence of the strong inducer carbamazepine.
Antivir Ther. 2025;30:13596535251335080. PubMedAbstract available
LABATE L, Rossetti B, Russo C, Cassol C, et al Durability of multi-drug antiretroviral therapy (mega-ART) in
treatment-experienced people with HIV in the ARCA database.
Antivir Ther. 2025;30:13596535251317054. PubMedAbstract available
February 2025
PICKERING RT, Asundi A, Olson A, Soden K, et al Increased insulin resistance following switch from efavirenz to
cobicistat-boosted elvitegravir.
Antivir Ther. 2025;30:13596535251314571. PubMedAbstract available
December 2024
PASSEROTTO RA, Lamanna F, Salvo PF, Iannone V, et al Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as
switch strategy in virologically-suppressed patients: real world data from a
monocentric cohort.
Antivir Ther. 2024;29:13596535241306467. PubMedAbstract available
April 2024
VAN HEMELRYCK S, Van Landuyt E, Hufkens V, Vanveggel S, et al Assessment of swallowability and acceptability of scored
darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose
combination (FDC) tablets in HIV-1-infected children aged >/=6 to <12 years, using
matching placebo tablets: A ran
Antivir Ther. 2024;29:13596535241248282. PubMedAbstract available